Blade Therapeutics updates enrollment progress for Covid-19 pneumonia study of BLD-2660

Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients.